Biomea Fusion (BMEA) Competitors $6.44 +0.06 (+0.94%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BMEA vs. CHMA, EPZM, ABOS, PRTK, OVID, SEPN, NUVB, IMTX, AVBP, and ETNBShould you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Chiasma (CHMA), Epizyme (EPZM), Acumen Pharmaceuticals (ABOS), Paratek Pharmaceuticals (PRTK), Ovid Therapeutics (OVID), Septerna (SEPN), Nuvation Bio (NUVB), Immatics (IMTX), ArriVent BioPharma (AVBP), and 89bio (ETNB). These companies are all part of the "medical" sector. Biomea Fusion vs. Chiasma Epizyme Acumen Pharmaceuticals Paratek Pharmaceuticals Ovid Therapeutics Septerna Nuvation Bio Immatics ArriVent BioPharma 89bio Biomea Fusion (NASDAQ:BMEA) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership. Is BMEA or CHMA more profitable? Chiasma's return on equity of -113.57% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% Chiasma N/A -113.57%-57.62% Does the media favor BMEA or CHMA? In the previous week, Biomea Fusion had 5 more articles in the media than Chiasma. MarketBeat recorded 5 mentions for Biomea Fusion and 0 mentions for Chiasma. Chiasma's average media sentiment score of 0.46 beat Biomea Fusion's score of 0.28 indicating that Chiasma is being referred to more favorably in the news media. Company Overall Sentiment Biomea Fusion Neutral Chiasma Neutral Which has stronger earnings & valuation, BMEA or CHMA? Chiasma has higher revenue and earnings than Biomea Fusion. Chiasma is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$4.01-1.61Chiasma$1.11M196.11-$74.78M-$1.43-2.63 Which has more volatility & risk, BMEA or CHMA? Biomea Fusion has a beta of -0.41, meaning that its stock price is 141% less volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Do insiders and institutionals hold more shares of BMEA or CHMA? 96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 61.7% of Chiasma shares are owned by institutional investors. 27.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 8.3% of Chiasma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend BMEA or CHMA? Biomea Fusion currently has a consensus price target of $30.50, suggesting a potential upside of 373.60%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Chiasma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00Chiasma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer BMEA or CHMA? Chiasma received 202 more outperform votes than Biomea Fusion when rated by MarketBeat users. However, 66.23% of users gave Biomea Fusion an outperform vote while only 48.75% of users gave Chiasma an outperform vote. CompanyUnderperformOutperformBiomea FusionOutperform Votes5166.23% Underperform Votes2633.77% ChiasmaOutperform Votes25348.75% Underperform Votes26651.25% SummaryBiomea Fusion beats Chiasma on 9 of the 17 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMEA vs. The Competition Export to ExcelMetricBiomea FusionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$233.39M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-1.6110.35102.4617.58Price / SalesN/A362.011,234.85158.43Price / CashN/A52.6040.4736.33Price / Book3.0710.377.096.50Net Income-$117.25M$153.60M$119.65M$226.22M7 Day Performance-1.38%3.92%2.06%3.76%1 Month Performance-43.06%-6.78%-2.46%4.63%1 Year Performance-35.79%33.23%33.95%29.20% Biomea Fusion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMEABiomea Fusion3.5211 of 5 stars$6.44+0.9%$30.50+373.6%-35.8%$233.39MN/A-1.6150Analyst ForecastCHMAChiasmaN/A$3.76flatN/A+0.0%$217.68M$1.11M-2.6385EPZMEpizymeN/A$1.47flatN/A+0.0%$247.44M$37.43M-0.85250ABOSAcumen Pharmaceuticals2.6819 of 5 stars$2.31-2.5%$9.00+290.5%+0.4%$138.48MN/A-1.6751PRTKParatek PharmaceuticalsN/A$2.23+1.8%N/A+0.0%$127.82M$160.27M-2.03268Analyst ForecastHigh Trading VolumeOVIDOvid Therapeutics4.4383 of 5 stars$1.06+1.9%$4.04+281.1%-68.6%$75.27M$390,000.00-2.2660Analyst RevisionSEPNSepternaN/A$21.79-3.2%$43.67+100.4%N/A$915.18MN/A0.00N/AAnalyst ForecastAnalyst RevisionNews CoverageNUVBNuvation Bio2.3507 of 5 stars$2.70+4.7%$6.60+144.4%+122.6%$908.74MN/A-1.2460High Trading VolumeIMTXImmatics2.0648 of 5 stars$7.61-2.4%$16.67+119.0%-7.3%$908.33M$58.44M-11.53260Analyst ForecastAnalyst RevisionAVBPArriVent BioPharma1.1193 of 5 stars$26.59-3.0%$36.80+38.4%N/A$896.08MN/A0.0040ETNB89bio1.4858 of 5 stars$8.38+5.0%$30.33+262.0%+15.3%$889.37MN/A-2.8840 Related Companies and Tools Related Companies CHMA Alternatives EPZM Alternatives ABOS Alternatives PRTK Alternatives OVID Alternatives SEPN Alternatives NUVB Alternatives IMTX Alternatives AVBP Alternatives ETNB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BMEA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
